

May 25, 2021

### **Burgeoning Local Demand Underpins Performance**

#### **Revenue Soars Despite Zero Exports From Nigeria**


In Q1:2021, Dangote Cement Plc (DANGCEM) put up an impressive performance, with a total revenue of NGN332.65bn (up by 33.50% from NGN249.18bn in Q1:2020). The cement maker continued to milk its cash cow (the Nigerian market) as it realized revenue to the tune of NGN239.68bn (vs NGN179.34bn in Q1:2020) from Nigeria alone. Overall, the stellar group performance was supported by the burgeoning demand for housing infrastructure and commercial construction in its home market, which boosted cement sales. Although it had to place a hold on cement exports during the period to meet local demand, sales volume from its Nigerian operations reached a record high 4,901 Kilotons (22.20% up from 4,018 Kilotons in Q1:2020). Among its Pan-African businesses, Congo, Zambia, and Sierra Leone stood out with growth of 57.00%, 47.00%, and 39.00% in sales volume year-on-year, respectively. Other Pan-African operations also put up laudable performances, save for Ethiopia where sales volumes declined by 4.00% YoY due to plant maintenance. Thus, total sales volume and revenue from its Pan-African businesses increased by 12.80% and 33.10% to 2,613 Kilotons and NGN92.97bn (vs 2,316 Kilotons and NGN69.85bn in Q1:2020), respectively. We acknowledge the increasing participation of the private sector in real estate development and we expect this to support sales volumes for the rest of the year. We also retain our positive outlook on exports following management's guidance on resuming exports via its terminals in Q2. On this note, we revise our revenue forecast to NGN1.22trn for 2021FY (previously NGN1.18trn).

#### **Margins Shun Finance Cost Pressures**

We like that DANGCEM is not relenting on its efforts to contain growing costs. The commissioning of a new power plant in Tanzania as well as the modern and enhanced fifth line in its Obajana plant in Nigeria yielded some efficiency gains for the cement maker. While cost of sales for the period shot up by 22.69%, fueled by an increase in cost of raw materials (+59.25%) and fuel (+21.44%), the impact was offset by the growth in topline as cost-to-sales ratio moderated to 38.48% (vs 41.87% in Q1:2020). Operating Expenses for the period ticked higher by 4.84%, mainly driven by the increase in administrative expenses (+22.80%) and haulage expenses (+16.04%). However, we note the significant cost savings recorded on advertisement expenses (-84.71%) and salaries (-9.77%). Thus, EBITDA advanced by 55.81% to NGN177.97bn (vs 114.22bn in Q1:2020). Payment of accrued interest on the company's borrowings as well as a realized foreign exchange loss of NGN10.62bn resulted in higher net finance costs (+481.49%) of NGN21.64bn. The company is in the process of raising a NGN300bn bond to meet maturing short-term obligations, finance ongoing expansions projects, and support working capital requirements. Armed with a long term "AAA" rating by GCR and considering the relatively low interest rate environment, our assessment is that it will be able to access the debt at a favourable rate. Ultimately, this should support the company's drive for debt sustainability as it seeks to sustain an optimal capital structure (debt-to-equity at 0.44x).

Overall, Profit before tax and Profit after tax improved by 47.75% and 48.06% to NGN130.10bn and NGN89.71bn, respectively. Consequently, there was a notable improvement in profitability ratios for the period as Net margin, ROE and ROA advanced to 26.97%, 9.24%, and 4.23% from 24.32%, 6.39%, and 3.37%, respectively.

Company	DANGCEM
Valuation	
Trailing EPS	17.91
BVPS	56.99
P/E	11.73x
P/BV	3.68x
Target EV/EBITDA	7.83x
Dec-2021 Exp. EBITDA	556.93bn
Dec 2021 Target price	232.64
Current Price	210.00
Up/Downside Potential	+10.78%
Ratings	BUY
Key metrics	
ROE	31.42%
ROA	14.39%
Net margin	26.97%
Asset Turnover	0.53x
Leverage	2.18x
Share/Share Price	
Statistics	
Yr Hi	244.90
Yr Lo	204.00
YTD return	-14.25%
Beta	1.34
Adjusted Beta	1.23
52-wk average volume	1.64mn
Shares outstanding	17.04bn
Market cap [NGN]	3.58trn
Financial year end	December
Most Recent Period	
(MRP)	Q1:2021





May 25, 2021

#### Recommendation

We maintain our EBITDA projection of NGN556.93.bn and an EV/EBITDA of 7.83x. Thus, we retain our target price at NGN232.64, implying an upside potential of 10.78% when compared to its closing price of NGN210.00 on May 25, 2021. Hence, we rate the counter as **BUY**.

**Chart 1: Sensitivity Analysis** 

Sensitivity Analysis of Dec-2021 Target Price to key model inputs					Min	213.48		
			EBITDA per share				Max	252.61
		31.45	32.11	32.76	33.42	34.07	_	
	7.52x	213.48	217.93	222.37	226.82	231.27	_	
Target	7.67x	218.40	222.95	227.50	232.05	236.60		
EV/EBITDA	7.83x	223.33	227.98	232.64	237.29	241.94		
	7.99x	228.26	233.01	237.77	242.52	247.28		
	8.14x	233.18	238.04	242.90	247.75	252.61	_	

Financial Highlights	(NGN million)	) Q1:2021 Financia	l Result
----------------------	---------------	--------------------	----------

Profit & Loss Account	Q1:2021	Q1:2020	y/y Growth
Revenue	332,651	249,182	33.50%
Cost of Sales	127,996	104,325	22.69%
Gross Profit	204,655	144,857	41.28%
Investment Income	3,654	5,290	-30.93%
Other Income	3,912	1,122	248.66%
Operating Expense	56,823	54,200	4.84%
Finance cost	25,297	9,012	180.70%
PBT	130,101	88,057	47.75%
PAT	89,710	60,592	48.06%
Balance Sheet	Q1:2021	2020FY	
Inventories	129,046	108,270	19.19%
Trade and Other Receivables	33,601	35,194	-4.53%
Cash and bank	147,871	145,835	1.40%
Property, Plant and Equipment	1,377,311	1,390,687	-0.96%
Other Assets	433,411	342,465	26.56%
Total Assets	2,121,240	2,022,451	4.88%
Shareholders' fund	971,160	890,970	9.00%
Trade and Other Payables	398,415	349,388	14.03%
Tax Liabilities	98,004	59,781	63.94%
Total Liabilities	1,150,080	1,131,481	1.64%



May 25, 2021

### **Contact Information**

**Brokerage and Retail Services** 

topeoludimu@meristemng.com (+234 905 569 0627) olatunjifaniyi@meristemng.com (+234 803 446 3118) contact@meristemng.com

**Investment Banking/Corporate Finance** 

rasakisalawu@meristemng.com (+234 806 022 9889) seunlijofi@meristemng.com (+234 808 536 5766)

**Wealth Management** 

funmilolaadekola-daramola@meristemng.com (+234 805 498 4522)

crmwealth@meristemng.com

Tel: +234 01 738 9948

Registrars

muboolasoko@meristemregistrars.com (+234 803 324 7996) martinaosague@meristemregistrars.com (+234 802 303 1783)

www.meristemregistrars.com Tel: +23401-280 9250

**Trust Services** 

damilolahassan@meristemng.com (+234 803 613 9123) crmwealth@meristemng.com

**Group Business Development** 

saheedbashir@mersitemng.com (+234 802 454 6575) ifeomaogalue@meristemng.com (+234 802 3942967) emekaikpechukwu@meristemng.com (+234 803 791 5731) info@meristemng.com

**Client Services** 

adefemitaiwo@meristemng.com (+234 803 694 3034) blessingogwuche@meristemng.com (+234 706 896 5173)

car@meristemng.com

Investment Research

ahmedjinad@meristemng.com (+234 809 183 9487)

research@meristemng.com

**Corporate websites:** www.meristemng.com www.meristemwealth.com www.meristemregistrars.com

Meristem Research can also be accessed on the following platforms:

Meristem Research portal: meristem.com.ng/rhub

Bloomberg: MERI <GO>

Capital IQ: www.capitalig.com Reuters: www.thomsonreuters.com

**ISI Emerging Markets:** www.securities.com/ch.html?pc=NG

NSE: DANGCEM I Bloomberg: DANGCEM NL EQUITY I Reuters: DANGCEM

FactSet: www.factset.com



May 25, 2021

#### **Analyst's Certification and Disclaimer**

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

**Analysts' Compensation:** The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

#### **Investment Ratings**

#### Fair Value Estimate

We estimate a stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

#### **Target Price Estimate**

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

#### **Ratings Specification**

**BUY:** Target Price of the stock is above the current market price by at least 10 percent

HOLD: Target Price of the stock ranges between -10 percent and 10 percent from the current market price.

**SELL:** Target Price of the stock is more than **10 percent** below the current market price.



May 25, 2021

#### **Definitions**

**Price Targets:** Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

**Asset allocation:** The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

#### **Movements in Price Target**

Company Name: Dangote Cement Plc.

Date	Price (N)	Previous Target Price(N)	New Target Price (N)	Previous Recommendation	New Recommendation
25-May-2021	210.00	232.64	232.64	HOLD	BUY
29-Mar-2021	224.00	220.70	232.64	HOLD	HOLD
1-Jan-2021	244.90	200.06	220.70	HOLD	HOLD

#### **Company disclosures**

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

Company	Disclosure
Dangote Cement Plc.	

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek, or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stock broking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- k. Meristem is the registrar to the company.
- I. The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interest in the company.



May 25, 2021

#### **Conflict of Interest**

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

#### **Important Disclosure**

**For U.S. persons only:** This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Mersitem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

#### Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, the company through its subsidiaries carries out stock broking, wealth management, trustees and registrars businesses which are regulated by the SEC and ICMR.

Copyright 2021 Meristem Securities Limited. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Meristem Securities Limited.